Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT05807880Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, penpulimab, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Sep 2023; status: active, not recruiting.
02
Drugs
anlotinibpenpulimabcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05807880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807880.